Drug development

News round-up by DDW’s Megan Thomas for 11-15 October   For this week’s drug discovery round up, DDW’s Megan Thomas has selected five stories that showcase how organisations and collaboration within the drug discovery industry can provide researchers and drug developers with the tools they need to move forward with life-saving treatments.   Therapeutics research partnership to access induced […]

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application Science Team Lead, Carterra.  The background  […]

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with over 100 currently in clinical […]

DDW’s Editor Lu Rahman comments and gives perspective on the global drug discovery and development market in the UK. As I’m writing this in the UK, there are reports of gas supply shortages, a lack of CO2­ affecting food supply, the price of energy is rising and the cherry on top – murmurings of cancelling […]

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online triage of patients, and the sharing […]

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of the public had the opportunity to […]

Novartis has announced that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA), which the company says not only helps with sickle cell disease (SCD), but also demonstrates a commitment to supporting health equity for a community that has been historically underserved, without any new treatment options for […]

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should AstraZeneca advance any of the research programmes into its pipeline, VaxEquity could […]

Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences. Azenta will bring together Brookes’ existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions.  “We are excited to announce the creation of Azenta as it reinforces our commitment to helping customers reach […]

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by 2025.1 However, the value of […]